ASCO News In Brief: Glaxo Wellcome 506U
Executive Summary
Glaxo Wellcome 506U: Phase I 40-patient trial results show 9 complete remissions and three partial remissions out of 15 evaluable patients with acute T-cell lymphoblastic leukemia following treatment with 2-amino-methoxypurine arabinoside, 506U. Adverse reactions include dose-limiting neurotoxicity, mild-to-moderate nausea in one adult and mild conjunctivitis in two patients...